Anavex Life Sciences Corp.
AVXL • NASDAQ
Anavex Life Sciences Corp. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Christopher U. Missling, with a market cap of $261.3M.
CEOChristopher U. Missling
Next Earnings
Upcoming earnings announcement for Anavex Life Sciences Corp.
Date
Tuesday, May 12, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q2 2026
EPS Estimate
-$0.07
Earnings History
Past 12 earnings reports for Anavex Life Sciences Corp.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Q1 2026 | -$0.06Est: -$0.11 | +45.5% | - | — |  10-Q |
| Nov 25, 2025 | Q4 2025 | -$0.11Est: -$0.14 | +21.4% | - | — | 10-K |
| Aug 12, 2025 | Q3 2025 | -$0.16Est: -$0.14 | -14.3% | - | — | 10-Q |
| May 13, 2025 | Q2 2025 | -$0.13Est: -$0.15 | +13.3% | - | — | 10-Q |
| Feb 12, 2025 | Q1 2025 | -$0.14Est: -$0.17 | +17.6% | - | — | 10-Q |
| Dec 23, 2024 | Q4 2024 | -$0.14Est: -$0.17 | +17.6% | - | — | 10-K |
| Aug 6, 2024 | Q3 2024 | -$0.14Est: -$0.13 | -7.7% | - | — | 10-Q |
| May 9, 2024 | Q2 2024 | -$0.13Est: -$0.11 | -18.2% | - | — | 10-Q |
| Feb 7, 2024 | Q1 2024 | -$0.11Est: -$0.14 | +21.4% | - | — | 10-Q |
| Nov 27, 2023 | Q4 2023 | -$0.12Est: -$0.15 | +20.0% | - | — | — |
| Aug 8, 2023 | Q3 2023 | -$0.14Est: -$0.17 | +17.6% | - | — | 10-Q |
| May 9, 2023 | Q2 2023 | -$0.17Est: -$0.19 | +10.5% | - | — | — |